113results about "Antigen-carrier link" patented technology

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The present invention provides methods for inducing tolerance and / or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and / or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and / or suppress an immune response to the antigen.

The present disclosure provides methods of preparing heteroaryl-containing compounds, wherein an azide-alkyne cycloaddition is accelerated in the presence of lauryldimethylamine oxide (LDAO). The present disclosure further provides conjugates of polypeptides and antigens prepared using such methods.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

The invention belongs to the field of vaccine preparation, and particularly relates to a nano vaccine based on helicobacter pylori outer membrane vesicles as well as a preparation method and application of the nano vaccine. OMV and LPS of helicobacter pylori are used as antigens and adjuvants, DMON is used as a carrier, then electrostatic interaction is utilized to enable the DMON to adsorb LPS micromolecules, then a liposome extruder is utilized to uniformly wrap the helicobacter pylori OMV on the surface of a DMON nano material, and the nano vaccine based on helicobacter pylori outer membrane vesicles is obtained. In-vivo and in-vitro tests prove that the nano vaccine can be ingested by macrophages, the phagocytic ability of the macrophages is promoted, the level of secreting various immune cell factors by the macrophages is remarkably improved, and high-level antigen-specific humoral immunity, mucosal immunity and Th1 / Th2 / Th17 type cellular immune response can be induced in a mouse body.

The present invention provides methods for inducing tolerance and / or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and / or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and / or suppress an immune response to the antigen.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention relates to multivalent immunogenic compositions comprising one or more Streptococcus pneumoniae polysaccharide protein conjugates wherein each of the conjugates comprises a polysaccharide from a Streptococcus pneumoniae serotype conjugated to a carrier protein wherein the serotype of the Streptococcus pneumoniae is as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed from a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed from a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering to the patient the multivalent immunogenic composition of the invention. The multivalent immunogenic composition is used to provide protection against Streptococcus pneumoniae infection and / or pneumococcal disease caused by Streptococcus pneumoniae. The compositions of the invention are also useful as part of a therapeutic regimen that provides supplemental protection for patients who have been vaccinated with a multivalent vaccine for the prevention of pneumococcal disease.

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

To provide safe and effective means to induce tolerance to cedar pollen antigens (e.g., CRYJ1 and CRYJ2) in subjects that suffer from Japanese cedar pollinosis, or in subjects at risk for developing Japanese cedar pollinosis, taking account of the substantial prevalence of the disease, particularly in Japan and neighboring countries, and the likelihood of antibody cross-reactivity between conifer pollens.SOLUTION: The present invention provides compositions comprising particles with a negative zeta potential that encapsulate one or more epitopes associated with Japanese cedar pollen. Methods of inducing immunological tolerance to Japanese cedar pollen by administering the particles are also provided.SELECTED DRAWING: Figure 1

To provide a manufacturing condition related to conjugation of capsular polysaccharide from Streptococcus pneumoniae to carrier protein.SOLUTION: A method for producing a polysaccharide-protein conjugate includes allowing polysaccharide in first solution to react with protein in second solution to from third solution, and performing polysaccharide-protein conjugation reaction in the third solution to create a polysaccharide-protein conjugate, where the third solution contains at least 1 mM of salt. It is preferable that the salt be sodium salt, potassium salt, lithium salt, magnesium salt or calcium salt. A polyvalent pneumococcal vaccine can contain the polysaccharide-protein conjugate produced by using a process of the present invention.SELECTED DRAWING: Figure 1

Immunogens include an immunogenic carrier and an antigenic apoptosis-related spot-like protein containing a caspase activation and recruitment domain (ASC) peptide linked to the immunogenic carrier. In one or more embodiments, the immunogenic vector is a Q [beta] virus-like particle (VLP). The immunogen may be formulated as a composition useful in the treatment of inflammatory medical conditions.

Technologies for the prevention and / or treatment of pneumococcal infections.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

The present disclosure provides methods of preparing heteroaryl-containing compounds, wherein an azide-alkyne cycloaddition is accelerated in the presence of lauryldimethylamine oxide (LDAO). The present disclosure further provides conjugates of polypeptides and antigens prepared using such methods.

The invention relates to a preparation method of a babesiella bovis vaccine, belongs to the technical field of vaccines, and particularly relates to a combined vaccine based on silver nanoparticles (AgNPs) and theileria bovis antigen, the vaccine comprises 10-50nm AgNPs, the surface of the AgNPs is modified with carboxyl, amino or PEG, and the AgNPs are used for covalently coupling RAP-1 protein or immunogenic fragments thereof and MSA-2 protein or B cell epitope peptide thereof, the RAP-1 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 1), the MSA-2 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 2), and the preparation method comprises the following steps: carrier construction, recombinant expression, protein purification and AgNPs coupling to form a silver nanoparticle antigen compound, and the silver nanoparticle antigen compound is coated with chitosan to prolong the in-vivo half-life period.

To provide an improved process related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein, and a prepared serotype 35B polysaccharide-protein conjugate.SOLUTION: A serotype 35B S. pneumoniae polysaccharide-protein conjugate has a molecular weight of 1,000 kDa to 7,000 kDa. The conjugate comprises a lysine consumption of 3 mol / mol protein to 9 mol / mol protein. A process for making the conjugate comprises activation of the polysaccharide, wherein the activation utilizes periodate in a range of 0.01 to 0.1 moles of periodate per mole of polysaccharide repeating unit.SELECTED DRAWING: Figure 1A

To provide additional pneumococcal vaccine compositions which can provide protection against pneumococcal serotypes not present in currently available vaccines.SOLUTION: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, where each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein. In some embodiments, at least one polysaccharide protein conjugate is formed by a conjugation reaction comprising an aprotic solvent. In other embodiment, each of the polysaccharide protein conjugates are formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient.SELECTED DRAWING: Figure 1

The invention discloses a novel titanium-functionalized whole-tumor vaccine and a preparation method and application thereof.The preparation method comprises the steps that Lewis lung cancer cells are collected, washed and precipitated, normal saline is added for resuspension at the room temperature, TiBALDH is added at the same time, and the mixture is mixed to be uniform to obtain a mixed solution; oscillating and incubating the obtained mixed solution for a period of time, so that Ti in the mixed solution is in full contact with the tumor cells, and the Ti and the tumor cells are combined to form mineralized particles, thereby realizing biomimetic mineralization to obtain mineralized cells; and centrifuging and washing the obtained mineralized cells to obtain the titanium functionalized whole tumor cell vaccine. And finally adding ultrapure water and carrying out low-temperature resuspension preservation. The titanium-functionalized whole tumor cell vaccine prepared by the invention can enhance immunocompetence, stimulate DC maturation and play an immune activation role, can also retain that a complete tumor antigen can induce immune response without tumorigenic risk, and has good safety, so that the titanium-functionalized whole tumor cell vaccine is expected to be applied to tumor immunotherapy and has a relatively wide application prospect.

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions are described comprising conjugates of E. coli polysaccharide antigen O1, 02, 04, 06, 08, 015, 016, 018, 025, and 075 and further comprising 0153 or 021 or both 0153 and 021 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

Described herein is a tumor therapeutic composition or tumor vaccine which can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

The present invention provides immunoconjugates comprising an antigen and an F-actin-binding moiety. These immunoconjugates promote the presentation of antigens. The invention also provides vaccines that comprise or encode conjugates that allow antigens to be presented to the immune system. Related medical uses and methods of eliciting an immune response are also provided.

Provided herein are compositions and methods related to CMV gB proteins in which amino acid substitutions have been made to disrupt the postfusion state and / or stabilize the prefusion state.

The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate), and to the use thereof. The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate). The vaccine formulations of the present invention would typically include at least one glycoconjugate from Streptococcus pneumoniae serotype in a formulation designed to promote resuspension.

To provide additional pneumococcal vaccine compositions which can provide protection against pneumococcal serotypes not present in currently available vaccines.SOLUTION: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, where each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein. In some embodiments, at least one polysaccharide protein conjugate is formed by a conjugation reaction comprising an aprotic solvent. In other embodiment, each of the polysaccharide protein conjugates are formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient.SELECTED DRAWING: Figure 1

The present invention relates to: a conjugate comprising mRNA of an antigen protein and mRNA encoding a carrier protein linked to the 5' end and the 3' end of the mRNA of the antigen protein; and an immunization composition and / or vaccine composition comprising same. The present invention has the effect of stably increasing the expression of the antigen protein.